Drugs / SB11
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07550504 | Mar 2026 | age-related macular degeneration, central retinal vein occlusion with macular edema, choroidal neovascularization, occlusion of tributary of retinal vein | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06176963 | Nov 2023 | macular retinal edema, retinal vein occlusion, wet macular degeneration | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03150589 | Mar 2018 → May 2019 | age-related macular degeneration | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03150589 ↗ |
| Known as | Byooviz | “Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product” PMID 36520462 ↗ Feb 20231“SB11 (Byooviz™; Samsung Bioepis Co., Ltd.) is a ranibizumab” PMID 38976126 ↗ Jul 2024 |
| Route | Intravitreal | “Intravitreal injection of SB11 or RBZ, 0.5 mg, every 4 weeks through week 48.” PMID 36520462 ↗ Feb 2023 |